LEADER 01875oam  2200505   450 
001 9910706890203321
005 20180316110332.0
035   $a(CKB)5470000002458562
035   $a(OCoLC)852784168$z(OCoLC)654299303$z(OCoLC)777353954$z(OCoLC)1028572795$z(OCoLC)1028649918
035   $a(EXLCZ)995470000002458562
100   $a20130713d2002      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aExamining issues related to competition in the pharmaceutical marketplace $ea review of the FTC report, generic drug entry prior to patent expiration : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, June 13 and October 10, 2002
210  1$aWashington, DC :$cU.S.Government Printing Office,$d2002.
215   $a1 online resource (iii, 142 pages)
300   $a"Serial No. 107-140."
320   $aIncludes bibliographical references.
517   $aExamining issues related to competition in the pharmaceutical marketplace 
606   $aGeneric drugs
606   $aDrugs$xPrices$zUnited States
606   $aCompetition
606   $aPharmaceutical industry
608   $aLegislative hearings.$2lcgft
615  0$aGeneric drugs.
615  0$aDrugs$xPrices
615  0$aCompetition.
615  0$aPharmaceutical industry.
701   $aMuris$b Timothy J$01351335
801  0$bOCLCE
801  1$bOCLCE
801  2$bOCLCO
801  2$bOCLCQ
801  2$bOCLCA
801  2$bGPO
801  2$bOCLCF
801  2$bMERUC
801  2$bGPO
906   $aBOOK
912   $a9910706890203321
996   $aExamining issues related to competition in the pharmaceutical marketplace$93516799
997   $aUNINA